Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gabament
- Development stage
- Approved
- Lead developer
- Anthus Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Gabament is an oral small molecule formulation of gabapentin, a structural analog of gamma-aminobutyric acid (GABA), marketed by Anthus Pharmaceuticals. It exerts its therapeutic effects by binding with high affinity to the alpha-2-delta-1 subunit of voltage-gated calcium channels (VGCCs) in the central nervous system. This interaction reduces the calcium-dependent release of several excitatory neurotransmitters, including glutamate, norepinephrine, and substance P, thereby modulating neuronal excitability. Gabament is indicated for the management of various neuropathic pain conditions, such as postherpetic neuralgia, and as an adjunctive treatment for seizure disorders, specifically partial seizures.
- Brand names
- Gabament
- Other names
- gabapentin
02
Targets
CACNA2D2 (Voltage-gated calcium channel subunit alpha-2/delta-2)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)
Beyond the preview
Go deeper on Gabament.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gabament.